Program
alpha 1-Antitrypsin
Also written as “Alpha-1 MP”, “GLASSIA” and “Alpha1-proteinase inhibitor”.
Its studies are mostly in alpha 1-Antitrypsin Deficiency · Pulmonary Disease, Chronic Obstructive · Pulmonary Emphysema · Graft vs Host Disease · Diabetes Mellitus, Type 1, led by 4 companies.
Drug pageAlpha 1-Antitrypsin: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Grifolsits history only | 131 open or running | phase 3since Feb 20, 2006 | Sep 12, 2005 | Sep 2028phase 3 · NCT02796937 |
| Takedaits history only | 70 open or running | phase 4since Nov 3, 2006 | Nov 3, 2006 | none ahead |
| CSLits history only | 31 open or running | phase 4since Dec 2, 2005 | Dec 2, 2005 | Sep 15, 2033phase 4 · NCT07326592 |
| Kamada | 30 open or running | phase 3since Dec 17, 2019 | Feb 24, 2011 | none ahead |
Also a collaborator on its studies: Baxalta Innovations GmbH, now part of Shire.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Kamada only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 24, 2011First study: phase 2 study in Diabetes Mellitus, Type 1First studyNCT01304537 · 24 enrolled · Israel
- Nov 27, 2013Phase 2 study in Diabetes MellitusNCT02005848 · 70 enrolled · Israel
- Dec 17, 2019Phase 3 study in alpha 1-Antitrypsin DeficiencyNCT04204252 · 98 enrolled · Belgium, Finland, Ireland and more
TargetBeta
“Leukocyte elastase inhibitor”ChEMBL 37, by rule
Studies
All 3 Kamada leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04204252alpha 1-Antitrypsin Deficiency · Belgium, Finland, Ireland and more | 3 | Terminated | Feb 19, 2026 | 98 |
| NCT02005848Diabetes Mellitus · Israel | 2 | Completed | Feb 2017 | 70 |
| NCT01304537Diabetes Mellitus, Type 1 · Israel | 2 | Completed | Nov 2012 | 24 |
How it is read
Names in the registry
- “Alpha-1 MP”, 5 entries
- “GLASSIA”, 2 entries
- “Alpha1-proteinase inhibitor”, 2 entries
- “Alpha1-Proteinase Inhibitor (Human)”, 2 entries
- “CE1226”, 1 entry
Conditions, from the studies’ own filings
- alpha 1-Antitrypsin Deficiency, 12 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
- Pulmonary Emphysema, 2 studies
- Graft vs Host Disease, 2 studies
- Diabetes Mellitus, Type 1, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.